Hoersholm, Denmark, 03 March 2016
Hoersholm, Denmark; March 3rd, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that the screening protocol for APO010 in Multiple Myeloma (MM) has been approved by the Ethics Committee. APO010 is a first in class FASLigand anticancer product in the immuno-oncology field.
OV will now initiate the screening of approximately 150 patients at 4 sites at Danish hematology wards and identify 15 patients with the highest likelihood of APO010-benefit in a focused phase 2 multi center study. The Drug Response Predictor (DRPTM) uses genomic information from the individual cancer patient’s tumor. If the product already on shelf is approved, Phase 2 is expected to start Q2-Q3 2016.